Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE ISTO Technologies, Inc.
ST. LOUIS, Feb. 12, 2014 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held regenerative medicine company, announced today that Mitchell Seyedin, Ph.D., the Company's Executive Chairman, will present at the New York Stem Cell Summit 2014.
About ISTO Technologies, Inc.
ISTO is a privately-held a regenerative medicine company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company's proprietary cell-based platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in late stage clinical development, ISTO manufactures and markets InQu®, a differentiated bone graft extender and substitute in spinal fusion applications that has been used in over 28,000 surgeries at U.S. hospitals to date.
©2012 PR Newswire. All Rights Reserved.